CTLA4 and neoplasm: To address these challenges, various therapeutic strategies are being investigated, including immune checkpoint inhibitors that target PD-1 and CTLA-4, combined treatment regimens to enhance tumor immunogenicity, and innovative methods aimed at depleting immunosuppressive factors within the tumor milieu [38].